DiaSorin stock holds firm on FTSE MIB with limited fresh data
Published on 08/27/2026 at 21:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DiaSorin (ISIN IT0003497168) remains part of the FTSE MIB index, with DiaSorin stock shown in the latest yearly performance overview as trading at 75.66 on August 27, 2026, underscoring its role as a mid-cap healthcare name on the Italian market. That index table also reports a positive performance of 10.40 percent for the period covered, indicating that DiaSorin has posted a double-digit gain in the current measurement window. For investors, the presence of DiaSorin in the FTSE MIB signals both liquidity and relevance on Borsa Italiana.
The same FTSE MIB performance overview lists multiple constituents and shows DiaSorin with a last value of 75.66 compared with an earlier starting price of 68.53183, which explains the documented 10.40 percent increase in the table. This combination of last value and starting point yields a clear quantified comparison within the index context, highlighting that DiaSorin has outperformed its own past level over the tracked period. In an environment where sector peers may show more modest gains or flat performance, a move of 10.40 percent can be meaningful for long-term holders.
DiaSorin on Borsa Italiana
A separate quote page for the stock on Borsa Italiana lists several intraday metrics for the session, including a minimum price of 73.76, a maximum price of 76.66, and an official price of 75.294305 for DiaSorin shares. In addition, the reference closing price is reported as 74.86, which offers a direct comparison between the official intraday price and the prior closing level. The opening auction price of 73.84 and the closing auction price of 74.86 frame the range in which the stock has changed hands during the trading day.
The relationship between the official price of 75.294305 and the reference closing price of 74.86 suggests a modest intraday gain of around half a euro per share within the same trading session. With a minimum of 73.76 and a maximum of 76.66 recorded, DiaSorin stock has traded within a band of less than 3 euros between the session low and high, which indicates a contained volatility profile on August 27, 2026. For investors looking at daily moves rather than long-term trends, this range can help assess short-term trading opportunities and risk.
Index performance context
Within the FTSE MIB yearly performance list, DiaSorin appears alongside other Italian names such as Campari, where DiaSorin is shown with a performance figure of 10.40 percent for the measurement period. That percentage reflects the change from the earlier price of 68.53183 to the last value of 75.66 in the same table, offering a straightforward numerical view of how DiaSorin has progressed over time. While the FTSE MIB contains many sectors from banking to industrials, DiaSorin’s positive contribution supports the broader index performance narrative.
Because the FTSE MIB table is compiled for August 27, 2026, it provides a dated snapshot of how the constituent stocks, including DiaSorin, have done over the relevant window. If an investor compares DiaSorin’s 10.40 percent gain to other names in the list, they gain context on whether the stock is outperforming or lagging the Italian market benchmark. This type of quantified comparison is valuable for portfolio allocation decisions, as it translates abstract performance into exact percentage figures.
Diagnostics portfolio
DiaSorin’s core business in in vitro diagnostics remains centered on specialty assays and instruments used by clinical laboratories. The company’s portfolio traditionally includes immunodiagnostics systems designed to measure markers for infectious diseases, oncology, endocrinology, and other therapeutic areas. These products are installed worldwide in hospital labs and reference centers, where reliability and accurate measurement are critical.
In addition to immunodiagnostics, DiaSorin has expanded into molecular diagnostics, offering assays that detect viral and bacterial genetic material through PCR-based technologies. This mix of specialty immunoassays and molecular tests provides laboratories with tools to manage routine and emergent diagnostic needs. For investors, the breadth of the product portfolio helps explain why DiaSorin has secured a stable position in the FTSE MIB despite short-term fluctuations in its share price or earnings cycle.
DiaSorin stock level
As of August 27, 2026, DiaSorin stock trades on Borsa Italiana with an official price of 75.294305 and a reference closing price of 74.86, framed by an intraday range between 73.76 at the low and 76.66 at the high. These figures show the current price zone in which the market values the company’s diagnostics franchise during the latest completed trading session. For market participants, the modest intraday gain from the prior close to the official price complements the larger 10.40 percent performance figure seen in the FTSE MIB table, sketching both short-term and period-long developments in tangible numbers.
Fact box
Company: DiaSorin S.p.A.
ISIN: IT0003497168
Ticker: DIAS
Exchange: Borsa Italiana (FTSE MIB constituent)
Price (as of August 27, 2026, latest official session): 75.294305 in the home-market currency
Sector / Industry: Healthcare diagnostics
Investor Relations
Company investor information is available on the official DiaSorin investor section, which provides access to regulatory filings, presentations, and financial reports, offering deeper insight into its diagnostics strategy and capital allocation.
